Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto.
Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and Development department, enabling significant scientific milestones in the fields of respiratory, neonatal, and rare disease therapies.
These successes have earned Paolo Chiesi noteworthy recognition, such as the honorary title of Doctor of Medicine and Surgery bestowed upon him by the University of Modena and Reggio Emilia in 2010, and the Honorary Degree from the Karolinska Institutet in Stockholm in 2019, in acknowledgment of his decades-long commitment to treating respiratory distress syndrome in premature infants.
In 2023, he became a Honorary President of the Chiesi Group.
His presence has been an inspiration to all those privileged to collaborate with him, thanks to his extraordinary scientific knowledge and exceptional humanity.
His passing leaves a huge void in all those who knew him.
About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
